Meridian Bioscience, Inc.  

(Public, NASDAQ:VIVO)   Watch this stock  
Find more results for Meridian Bioscience, Inc
0.00 (0.00%)
Real-time:   3:59PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.68 - 19.04
52 week 15.56 - 21.33
Open 18.97
Vol / Avg. 134,210.00/268,625.00
Mkt cap 797.88M
P/E 22.79
Div/yield 0.20/4.21
EPS 0.83
Shares 41.71M
Beta 1.41
Inst. own 91%
Jul 22, 2015
Q3 2015 Meridian Bioscience Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 6, 2015
Meridian Bioscience Inc at Deutsche Bank Health Care Conference - 12:50PM EDT - Add to calendar
May 5, 2015
Meridian Bioscience Inc at Robert W. Baird & Co. Inc's Growth Stock Conference - 9:30AM EDT - Add to calendar
Apr 23, 2015
Q2 2015 Meridian Bioscience Inc Earnings Release
Mar 4, 2015
Meridian Bioscience Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 19.54% 18.40%
Operating margin 30.52% 27.75%
EBITD margin - 30.69%
Return on average assets - 19.65%
Return on average equity - 21.98%
Employees 550 -
CDP Score - -


3471 River Hills Dr
United States - Map
+1-513-2713700 (Phone)
+1-513-2713762 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Officers and directors

John A. Kraeutler Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Melissa A. Lueke Chief Financial Officer, Executive Vice President, Secretary
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marco G. Calzavara President and Managing Director of Meridian Bioscience Europe
Age: 60
Bio & Compensation  - Reuters
Lawrence J. Baldini Executive Vice President - Operations and Information Systems
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard L. Eberly Executive Vice President; President of Meridian Life Science
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Vecheslav A. Elagin Ph.D. Executive Vice President - Research and Development
Age: 47
Bio & Compensation  - Reuters
Susan D. Rolih Executive Vice President - Regulatory & Quality Systems
Age: 65
Bio & Compensation  - Reuters
Michael C. Shaughnessy Executive Vice President; President of Meridian Diagnostics
Age: 58
Bio & Compensation  - Reuters
Marviette D. Johnson Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
David C. Phillips Lead Independent Director
Age: 76
Bio & Compensation  - Reuters